Drug
Astragalus mongholicus root polysaccharides clinical trials
Also written PG2.
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
PhytoHealth Corporation (10) · Taipei Medical University (1) · China Medical University Hospital (1)
Studies
Open first, then newest update. How each study uses astragalus mongholicus root polysaccharides is read from its arms, and is right about nine times in ten.
Testing it · 12
- PG2 Breast Cancer Evaluation in Adjuvant Medicine StudyCompletedPhase 2PhytoHealth CorporationNCT03314805Written as Astragalus polysaccharides 500 mg
- PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced MalignancyCompletedPhase 1/2PhytoHealth CorporationNCT01696565Written as PG2
- PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative CareCompletedPhase 4PhytoHealth CorporationNCT01720550Written as Astragalus Polysaccharides 500 mg
- PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal CancerCompletedPhase 2PhytoHealth CorporationNCT03611712Written as Astragalus Polysaccharides 500 mg
- Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) PatientsCompletedPhase 2PhytoHealth CorporationNCT00860600Written as PG2
- The Pilot Clinical Study of PG2 Injection on Hemorrhagic StrokeCompletedEarly Phase 1PhytoHealth CorporationNCT01325233Written as PG2
- PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative CareCompletedPhase 2/3PhytoHealth CorporationNCT00523107Written as PG2
- Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in FatigueTerminatedPhase 2/3PhytoHealth CorporationNCT00518869Written as PG2
- A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent ChemoradiotherapyTerminatedPhase 2PhytoHealth CorporationNCT01720563Written as Astragalus polysaccharides 500 mg
- Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for CancerWithdrawnPhase 2PhytoHealth CorporationNCT02077621Written as PG2
- Effects of PG2 on Fatigue-Related Symptom ClustersCompletedNot applicableTaipei Medical UniversityNCT02740959Written as Astragalus Polysaccharides 500 mg
- PG2 Injection 500 mg in Acute Stroke Study (Pass)CompletedPhase 2China Medical University HospitalNCT01603667Written as PG2
Codes
What other systems call astragalus mongholicus root polysaccharides · ClinicalTrials.gg INT015374
- UNII (FDA) 71WW2LNL50ASTRAGALUS MONGHOLICUS ROOT POLYSACCHARIDESOne source FDA
- RxNorm 2532931One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 71WW2LNL50 | ASTRAGALUS MONGHOLICUS ROOT POLYSACCHARIDES | One source FDA |
| RxNorm | 2532931 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.